The Pharmacology of SR 141716A: A Review
- 1 March 1999
- journal article
- review article
- Published by Wiley in CNS Drug Reviews
- Vol. 5 (1) , 43-58
- https://doi.org/10.1111/j.1527-3458.1999.tb00085.x
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonistBritish Journal of Pharmacology, 1997
- Endogenous cannabinoids as an aversive or counter-rewarding system in the ratNeuroscience Letters, 1997
- The Cubic Ternary Complex Receptor-Occupancy Model III. Resurrecting EfficacyJournal of Theoretical Biology, 1996
- Cannabinoid receptor stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding in rat brain membranesLife Sciences, 1996
- Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brainLife Sciences, 1996
- The Cubic Ternary Complex Receptor–Occupancy Model II. Understanding Apparent AffinityJournal of Theoretical Biology, 1996
- The Cubic Ternary Complex Receptor–Occupancy Model I. Model DescriptionJournal of Theoretical Biology, 1996
- Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysisLife Sciences, 1996
- Biochemical and pharmacological characterisatioN OF SR141716A, the first potent and selective brain cannabinoid receptor antagonistLife Sciences, 1995
- New dawn of cannabinoid pharmacologyTrends in Pharmacological Sciences, 1994